| Literature DB >> 25676134 |
Sébastien Mériaux1, Marianne Boucher1, Benjamin Marty2, Yoann Lalatonne3, Sandra Prévéral4, Laurence Motte3, Christopher T Lefèvre4, Françoise Geffroy1, Franck Lethimonnier1, Michel Péan4, Daniel Garcia4, Géraldine Adryanczyk-Perrier4, David Pignol4, Nicolas Ginet4.
Abstract
The fast development of sensitive molecular diagnostic tools is currently paving the way for a personalized medicine. A new class of ultrasensitive magnetic resonance imaging (MRI) T₂-contrast agents based on magnetosomes, magnetite nanocrystals biomineralized by magnetotactic bacteria, is proposed here. The contrast agents can be injected into the blood circulation and detected in the picomolar range. Purified magnetosomes are water-dispersible and stable within physiological conditions and exhibit at 17.2 T a transverse relaxivity r₂ four times higher than commercial ferumoxide. The subsequent gain in sensitivity by T₂(*) -weighted imaging at 17.2 T of the mouse brain vasculature is evidenced in vivo after tail vein injection of magnetosomes representing a low dose of iron (20 μmoliron kg(-1)), whereas no such phenomenon with the same dose of ferumoxide is observed. Preclinical studies of human pathologies in animal models will benefit from the combination of high magnetic field MRI with sensitive, low dose, easy-to-produce biocompatible contrast agents derived from bacterial magnetosomes.Entities:
Keywords: brain molecular imaging; contrast agents; magnetosome
Mesh:
Substances:
Year: 2015 PMID: 25676134 DOI: 10.1002/adhm.201400756
Source DB: PubMed Journal: Adv Healthc Mater ISSN: 2192-2640 Impact factor: 9.933